Europe's Natural Gas Refill Emergency: Asia Snatches Supply with Higher Prices, Can Winter Stock Be Replenished?

Publicado em 2026-08-21Última atualização em 2026-08-21

Resumo

The pace of European natural gas inventory replenishment is slower than in previous years, with storage levels expected to reach only 69% to 84% by early November. Asian buyers are offering higher prices, prompting U.S. LNG cargoes to divert. If Europe wants to build up a sufficient safety cushion before winter, it must increase its bids to compete for limited supplies.

Abstract

The pace of natural gas inventory replenishment in Europe is slower than in previous years, with the stock level expected to reach only 69% to 84% by early November. Asian buyers are offering higher prices, causing U.S. LNG shipments to divert. If Europe wants to build a sufficient safety cushion before winter, it can only compete for the limited supply by raising its bids.

Mid-August has passed, yet the European natural gas market is still worrying about winter stocks. Citing calculations by energy market intelligence firm Montel, Euronews reported that by November 1, Europe's natural gas inventory level might only be between 69% and 84%, essentially making the EU's original 90% target unattainable. Even when measured against the already relaxed requirements, the current refill rate seems inadequate.

This is not just a problem confined to inventory tables. Lower inventories mean a thinner buffer available during cold snaps or supply disruptions, and traders will also start bidding up winter supply prices earlier. The upward pressure on European natural gas prices recently largely stems from this situation: time is running out, while available supply options are not increasing correspondingly.

Three Months to Close a Gap of 72 Shipments

Montel's statistics show that from April to July this year, Europe's net natural gas injections were 11% lower than the five-year average and 18% lower than the same period last year. Germany's situation is particularly tight, with a storage level of only 46% at the end of July.

From May to July, Europe received an average of about 105 LNG cargoes per month. To push inventories close to 80% by early November, it would normally need about 130 cargoes per month. However, due to an accumulated shortfall of approximately 72 cargoes, it would need to attract an average of over 140 LNG carrier shipments per month in August, September, and October. This number is difficult to achieve unless European prices rise significantly or LNG shipments resume through the Strait of Hormuz.

The most direct price logic here is simple: for Europe to pull cargoes back from other markets, it needs to offer higher prices. The closer the refill deadline gets, the less room buyers have to wait for lower prices, and the harder it becomes for supply premiums in winter contracts to fade.

U.S. LNG is Diverting to Asia

Another trouble Europe faces is that Asian buyers are currently willing to pay higher prices. From March to July, U.S. LNG shipments to China, Japan, South Korea, Taiwan (China), and India tripled, setting a record. In July alone, these five markets received more U.S. LNG than Europe for the first time.

For sellers, cargoes flow to destinations with higher returns. Since April, for much of the time, the profits from shipping U.S. LNG to Northeast Asia have been higher than shipping it to Northwest Europe, leaving Europe, which originally relied on incremental U.S. supply, in a more passive position. If Europe raises its bids, the costs of natural gas and electricity will rise; if it doesn't raise prices, inventories may remain at low levels before winter arrives.

This is also why this news supports natural gas prices. Europe and Asia are competing for the same batch of flexible LNG, which will drive up the price of global marginal cargoes. Demand at U.S. export terminals will also remain strong as a result, indirectly supporting trading benchmarks based on U.S. natural gas. Of course, short-term fluctuations in NATGASUSDT will still be influenced by weather, U.S. inventories, and production, but Europe's current refill gap removes a layer of buffer from the global natural gas supply chain.

Before November, what the market really needs to digest is not whether the 90% target can be adjusted on paper, but whether Europe can increase its monthly arrivals from around 105 cargoes to over 140 cargoes for three consecutive months. As long as this gap persists, it will be difficult for natural gas prices to completely remove the risk of winter supply shortages.

Leituras Relacionadas

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

On August 19, J.P. Morgan (JPM) published a research report analyzing Moderna's recent Phase III trial success for its Individualized Neoantigen Therapy (INT), developed in partnership with Merck, in adjuvant melanoma. The trial met its primary endpoint of significantly improved recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. While JPM acknowledged the strong clinical value of these results, particularly the prevention of distant metastasis, the bank stated that this success was widely anticipated, with an 85% prior probability of success, and is already reflected in Moderna's current market valuation. Following the announcement, Moderna's stock rose in pre-market trading. However, JPM maintained its Underweight rating and $40 price target, implying approximately 36% downside from the current price of ~$63. The core rationale is that the success in adjuvant melanoma, a relatively small market in immuno-oncology, is fully priced in. Moderna's future valuation hinges entirely on INT's ability to demonstrate similar efficacy across broader cancer indications. JPM's valuation model incorporates only a modest risk-adjusted value (~$3/share) for the melanoma approval. Approximately $15/share of its target price is attributed to INT's potential in other cancer types. The report identifies upcoming data readouts in non-melanoma cancers (e.g., lung, head & neck, renal) as the critical variable that will determine the platform's ultimate value. Upside risks include better-than-expected data in these new indications, while downside risks involve clinical failures, regulatory delays, or commercial underperformance. In conclusion, JPM views the pre-market stock move as driven by short covering and trading sentiment rather than a fundamental re-rating. The bank remains bearish, arguing that Moderna must now prove INT's efficacy as a platform technology beyond melanoma to justify its current market cap.

marsbitHá 14m

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

marsbitHá 14m

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

The article discusses the U.S. Treasury's recent direct intervention to suppress long-term bond yields through buyback operations. While distinct from traditional Yield Curve Control (YCC), this move is interpreted as direct government intervention in its own financing costs. The author emphasizes the short-term tactical nature of this action and contrasts it with the Federal Reserve's upcoming, potentially divergent, policy stance at Jackson Hole. The core issue is framed as a long-term U.S. strategic dilemma: managing high deficit levels. The analysis argues that deficit reduction cannot realistically come from spending cuts or traditional industries, but must rely on achieving higher economic growth driven by technological breakthroughs. Current monetary tightening, while possibly curbing yields and inflation in the short term, is seen as potentially counterproductive to this necessary long-term investment in technology and supply chain resilience. The piece draws historical parallels, placing the current intervention between the 2000-2002 Treasury buybacks (for liquidity) and larger-scale Fed-led "Operation Twist" maneuvers. The effectiveness of the Treasury's action is deemed limited without Federal Reserve cooperation, which would signify a more significant policy shift. Ultimately, the author views such technical, bureaucratic interventions as treating symptoms rather than the underlying disease of the U.S. economy's structural challenges and "K-shaped" divergence. The conclusion suggests that sustained yield suppression by the Fed, combined with specific geopolitical outcomes, could serve as a catalyst for a more profound discussion on broader U.S. and dollar trajectory.

marsbitHá 14m

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

marsbitHá 14m

Trading

Spot
活动图片